Skip to main content
. 2023 May 11;21:318. doi: 10.1186/s12967-023-04184-6

Fig. 2.

Fig. 2

Nivolumab therapy modifies the alterations of CD26high frequencies. Box plots showing the median (25th; 75th percentile) distribution of CD26neg (A), CD26int (B), and CD26high (C) in a sub-cohort of 33 melanoma patients at baseline and after 12 weeks (W1) of nivolumab treatment. Representative dot plots illustrating CD26 subsets melanoma patients at W0 and W1 are depicted in D and E respectively